Histogenics Corporation (NASDAQ:HSGX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday. The brokerage presently has a $2.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 4.17% from the stock’s current price.

According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “

A number of other analysts have also commented on the stock. ValuEngine lowered shares of Histogenics Corporation from a “sell” rating to a “strong sell” rating in a research note on Monday, August 14th. Canaccord Genuity reaffirmed a “buy” rating and set a $4.00 price objective on shares of Histogenics Corporation in a research note on Friday, August 11th. Finally, HC Wainwright set a $4.00 price objective on shares of Histogenics Corporation and gave the company a “buy” rating in a research note on Friday, August 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $5.25.

Histogenics Corporation (NASDAQ:HSGX) opened at 1.92 on Thursday. The firm’s market cap is $43.18 million. Histogenics Corporation has a 12 month low of $1.45 and a 12 month high of $3.75. The firm’s 50-day moving average is $1.83 and its 200-day moving average is $1.75.

Histogenics Corporation (NASDAQ:HSGX) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.06. During the same quarter in the prior year, the business posted ($0.61) EPS. Equities analysts expect that Histogenics Corporation will post ($1.09) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Upgrades Histogenics Corporation (HSGX) to “Buy”” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/09/zacks-investment-research-upgrades-histogenics-corporation-hsgx-to-buy.html.

A hedge fund recently raised its stake in Histogenics Corporation stock. Sabby Management LLC lifted its stake in Histogenics Corporation (NASDAQ:HSGX) by 15.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,095,422 shares of the biotechnology company’s stock after purchasing an additional 150,531 shares during the quarter. Sabby Management LLC owned 5.31% of Histogenics Corporation worth $1,895,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 50.08% of the company’s stock.

About Histogenics Corporation

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Receive News & Stock Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related stocks with our FREE daily email newsletter.